Medicis Can't Duck Acne Med Suit Under Intermediary Doctrine

Law360, Washington (January 30, 2015, 5:29 PM EST) -- An intermediate Arizona appeals court on Thursday revived a suit accusing Medicis Pharmaceutical Corp. of misleading consumers about the side effects of the acne medication Solodyn, departing from the so-called learned intermediary doctrine that it has followed for decades.

The first division of the Arizona Court of Appeals found that although the court had used the doctrine since 1978, it's no longer appropriate. The prescription-drug manufacturer shouldn't be shielded from liability for its own actions in distributing a product simply because another actor in the chain of distribution is expected to act, according to the decision.

"While it is true that...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Attached Documents

Related Sections

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!